This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Ardoin, S. Articles by Schanberg, L. Search for Related Content PubMed Articles by Ardoin, S. Articles by Schanberg, L. Social Bookmarking                   What's this?

Review: Management of dyslipidemia in children and adolescents with systemic lupus erythematosus

Department of Pediatrics, Duke University Medical Center, Durham, NC, USA, stacy.ardoin{at}duke.edu

C. Sandborg

Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA

LE Schanberg

Department of Pediatrics, Duke University Medical Center, Durham, NC, USA

Systemic lupus erythematosus (SLE) is an independent risk factor for atherosclerosis, placing children and adolescents with SLE at great risk for developing cardiovascular sequelae, including myocardial infarction, in adulthood. Dyslipidemia and other traditional cardiac risk factors occur frequently in pediatric SLE and are often under-recognized and under-treated. Two dyslipidemia patterns are evident in pediatric SLE. Active disease is characterized by elevated triglycerides (TG) and low high density lipoprotein (HDL). With SLE treatment HDL and TG often normalize, while total cholesterol and low density lipoprotein (LDL) rise. The complex pathophysiology of dyslipidemia in SLE involves cytokines, autoantibodies, disease activity, medications, diet, and physical activity level, as well as other factors. Routine screening for dyslipidemia with fasting lipid profiles is indicated for children and adolescents with SLE. If lipoprotein levels are abnormal, first line therapy involves diet and exercise interventions for a minimum of six months. For persistent dyslipidemia, several pharmacologic therapies are available. Hydroxychloroquine, a common treatment for SLE, can improve lipid profiles and should be considered for all patients with SLE. Statins and bile acid sequestrants are typically added first for dyslipidemia, while niacin and fibrates are reserved for refractory disease and optimally prescribed in a multidisciplinary lipid clinic. Future research is needed to further illuminate the mechanisms of dyslipidemia in pediatric SLE with well designed clinical trials to determine the safest and most effective interventions to correct lipid profiles and prevent atherosclerosis. Lupus (2007) 16, 618—626.

Key Words: atherosclerosis • cardiovascular • lipid • pediatric • systemic lupus erythematosus

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. Nojima, Y. Masuda, Y. Iwatani, H. Kuratsune, Y. Watanabe, E. Suehisa, T. Takano, Y. Hidaka, and Y. Kanakura Arteriosclerosis obliterans associated with anti-cardiolipin antibody / {beta}2-glycoprotein I antibodies as a strong risk factor for ischaemic heart disease in patients with systemic lupus erythematosus Rheumatology, May 1, 2008; 47(5): 684 - 689. [Abstract] [Full Text] [PDF]